Drugs / A/Indonesia/05/05
A/Indonesia/05/05
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT00703053 | Sep 2008 → Jul 2009 | influenza | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT01788228 | Mar 2013 → Mar 2014 | influenza | GlaxoSmithKline | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | A/Indonesia/05/05 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00703053 ↗ |
| Known as | A/Indonesia/05/2005 | “Recent H5 disease has been caused by antigenically divergent H5 viruses, including A/Indonesia/05/2005 (a clade 2 H5 virus).” PMID 21282194 ↗ Jan 2011 |
| Known as | Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted (A/Indonesia) | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01788228 ↗ |
| Modality | Vaccine | “GSK Biologicals' vaccine GSK1557484A” NCT01788228 ↗ |
| Route | Intramuscular | “administered intramuscularly (IM) in deltoid region of arm” NCT01788228 ↗ |